Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 2, 2026, Curis, Inc. (the “Company”) received a letter (the “Delist Determination Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for th…
Filed Nov 6, 2026Accepted Nov 6, 2026, 4:30 PM ESTCIK 1108205Accession 0001104659-26-123906
We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.01Item 3.01 - Notice of Delisting
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
On November 2, 2026, Curis, Inc. (the “Company”)
received a letter (the “Delist Determination Letter”) from the Listing Qualifications Staff (the “Staff”) of The
Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for
the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital
Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). As the Company effected a 1-for-20 reverse
stock split on July 6, 2026, the Company is not eligible for any compliance period specified in Rule 5810(c)(3)(A) due
to the fact that, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company has effected a reverse stock split over the prior one-year
period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to
one. Additionally, following the Nasdaq Hearings Panel’s (the “Panel”) decision, dated July 24, 2026, the Company
is subject to a Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A) for a period of one year (the “Panel Monitor”).
The Company intends to make a timely request for a new hearing with the initial Panel or a newly convened Panel if the initial Panel is
unavailable, which will stay any further delisting actions. However, there can be no assurance that such appeal will be successful or
that the Company will remain listed on Nasdaq.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains
forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation,
any statements with respect to the Company’s intent to appeal the Delist Determination Letter, ability to receive a hearing with
any Panel or its ability to suspend or delay its delisting from Nasdaq. Forward-looking statements may contain the words "believes,"
"expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes,"
"predicts," "projects," "targets," "will," "may," "would," "could,"
"should," "continue," "potential," "focus," "strategy," "mission," or similar
expressions. Actual results may differ materially from those indicated by such forward-looking statements. Important factors that could
cause actual results to differ materially from those in these forward-looking statements include, but are not limited to, risks referenced
in Item 1A, “Risk Factors” of Part I of the Company’s Annual Report on Form 10-K for the year ended December 31,
2025, as such factors may be updated from time to time in other filings that the Company periodically makes with the SEC including, but
not limited to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026. In addition,
any forward-looking statements represent the views of the Company only as of the date of this Current Report on Form 8-K and should
not be relied upon as representing the Company’s views as of any subsequent date. The Company disclaims any intention or obligation
to update any of the forward-looking statements after the date of this Current Report on Form 8-K whether as a result of new information,
future events or otherwise, except as may be required by law.